Relationship between lipoprotein(a) and spontaneous recanalization of infarct-related arteries in the early phase of acute myocardial infarction

Clinical Cardiology

Volumn 31, Issue 5, 2008, Pages 211-216

  Jin, Won Kim ^a   Hong, Seog Seo ^a   Soon, Yong Suh ^a   Cheol, Ung Choi ^a   Eung, Ju Kim ^a   Rha, Seung Woon ^a   Chang, Gyu Park ^a   Dong, Joo Oh ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Acute myocardial infarction; Lipoprotein(a); Recanalization; Thrombolysis in myocardial infarction flow

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CORONARY ARTERY RECANALIZATION; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PROTEIN DETERMINATION; RETROSPECTIVE STUDY; RISK FACTOR; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; THROMBOSIS;

AGED; COHORT STUDIES; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VASCULAR PATENCY;

EID: 44449148756     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20143     Document Type: Article

References (22)

1. Marcovina SM, Koschinsky ML: A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment? Semin Vasc Med 2002;2:335-344
2. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, et al.: Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579-592
3. Scott J: Lipoprotein (a): thrombotic and atherogenic. Br Med J 1991;303:663
4. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, et al.: cDNA Sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987;330:132-137
5. Császár A, Karadi I, Juhasz E, Romics L: High lipoprotein (a) levels with predominance of high molecular weight apo(a) isoforms in patients with pulmonary embolism. Eur J Clin Invest 1995;25:368-370
6. Tavola A, Vigano D'Angelo S, Bandello F, Brancato R, Parlavecchia M, et al.: Central retinal vein and branch artery occlusion associated with inherited plasminogen deficiency and high lipoprotein (a) levels: a case report. Thromb Res 1995;80:327-331
7. Meekins JW, Pijnenborg R, Haussens M, van-Assche A, McFayden IR: Immunohistochemical detection of lipoprotein(a) in the wall of placenta bed spiral arteries in normal and severe preeclamptic pregnancies. Placenta 1994;15:511-524
8. Gensini GG: Coronary Angiography Mount Kisco, New York: Futura 1975
9. Lippi G, Giudi G: Lipoprotein(a): from ancestral benefit to modern pathogen? Q J Med 2000;93(2):75-84
10. Hajjar KA, Gavish D, Breslow J, Nachmann R: Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-305
11. Liu J, Harpel PC, Pannell R, Gurewich V: Lipoprotein(a): A kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator. Biochemistry 1993;32:9694-9700
12. Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM. et al.: Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995;1:256-259
13. Biemond BJ, Friederich PW, Koschinsky ML, Levi M, Sangrar W, etal.: Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation 1997;96:1612-1615
14. Dagdelen S, Eren N, Akdemir I, Karabulut H, Ergelen M, et al: The effect of lipoprotein-a on thrombolytic therapy and spontaneous reperfusion in acute myocardial infarction. A Comparative Study. Int Angiol 2002;21:384-389
15. Uusimaa P, Kervinen K, Kesiemi A, Peuhkurinen K: Serum lipoprotem(a) level in relation to severity of coronary artery disease and coronary artery patency in acute myocardial infarction. Heart Vessels 2002;16:37-41
16. Haider AW, Andreotti F, Thompson GR, Kluft C, Maseri A, et al.: Serum lipoprotein (a) level is related to thrombin generation and spontaneous intermittent coronary occlusion in patients with acute myocardial infarction. Circulation 1996;94(9):2072-2076
17. Matsuda S, Arima M, Ohigawa T, Tanimoto K, Takagi A, et al.: Relation between serum lipoprotein (a) and residual lesion stenosis of coronary artery after myocardial Infarction without reperfusion therapy. Jpn Heart J 2004;45:397-407
18. Moliterno DJ, Lange RA, Meidell RS, Willard JE, Leffert CC, et al.: Relation of plasma lipoprotein (a) to infarct artery patency in survivors of myocardial infarction. Circulation 1993;88:935-940
19. Motta M, Giugno I, Bosco S, Pistone G, Ruello P, et al.: Serum lipoprotein (a) changes in acute myocardial infarction. Panminerva Med 2001;43(2):77-80
20. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, et al.: Healed plaque ruptures and sudden coronary death evidence that subclinical rupture has a role in plaque progression. Circulation 2001;103:934-940
21. Lee HJ, Pae J, Sung K, Park SK, Chon CU, et al.: Distribution of serum lipoprotein(a) level and its association with other risk factors in apparently healthy Korean. Korean Circulation J 2006;36:150-158
22. Ojio S, Takatsu H, Tanaka T, Ueno K, Yokoya K, et al.: Considerable time from the onset of plaque rapture and/or thrombi until the onset of acute myocardial infarction in humans : coronary angiographic findings within 1 week before the onset of infarction. Circulation 2000;10:2063-2069